The NY Times with an obituary article on this doomed drug:
Nearly 9 of 10 doctors had “medium” or “high” awareness of the drug, the survey found. But more than half said they were concerned about Exubera’s safety. They were also concerned about its price and the bulkiness of the Exubera inhaler.
Because many doctors seem to have made up their minds about Exubera, Mr. Grofik said, Pfizer will face an uphill battle as it tries to change their views.
